• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re-challenge treatment of small-molecular inhibitors in NSCLC patients beyond progression.

作者信息

Tu Lingli, Sun Lan

机构信息

Division of Thoracic Cancer, Cancer Center, West China Hospital, West China School of Clinical Medicine, Sichuan University, Chengdu, China;

出版信息

J Thorac Dis. 2012 Dec;4(6):647-9. doi: 10.3978/j.issn.2072-1439.2012.10.14.

DOI:10.3978/j.issn.2072-1439.2012.10.14
PMID:23205294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3506798/
Abstract
摘要

相似文献

1
Re-challenge treatment of small-molecular inhibitors in NSCLC patients beyond progression.非小细胞肺癌患者疾病进展后小分子抑制剂的再激发治疗。
J Thorac Dis. 2012 Dec;4(6):647-9. doi: 10.3978/j.issn.2072-1439.2012.10.14.
2
Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.IRENE试验（NVALT-16）的原理与研究设计：一项II期试验，旨在评估对作为一线或既往治疗使用的EGFR-TKI有反应的、具有激活型EGFR突变的晚期非小细胞肺癌患者再次使用易瑞沙的情况。
Clin Lung Cancer. 2015 Jan;16(1):60-6. doi: 10.1016/j.cllc.2014.07.008. Epub 2014 Aug 15.
3
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.T790M 突变与晚期 NSCLC 患者在 EGFR-TKI 治疗进展后更好的疗效相关。
Lung Cancer. 2014 Jun;84(3):295-300. doi: 10.1016/j.lungcan.2014.03.011. Epub 2014 Mar 15.
4
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.一代 EGFR-TKI 治疗失败的既往治疗的非小细胞肺癌患者中埃非替尼的再挑战。
Cancer Chemother Pharmacol. 2019 May;83(5):817-825. doi: 10.1007/s00280-019-03790-w. Epub 2019 Feb 13.
5
Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.晚期非小细胞肺癌进展后继续抑制表皮生长因子受体
Eur J Cancer. 2017 Jan;70:12-21. doi: 10.1016/j.ejca.2016.10.014. Epub 2016 Nov 17.
6
[Evaluation of the Efficacy and Safety of Platinum Doublet Re-Challenge Chemotherapy in Patients with Recurrent Advanced Non-Small Cell Lung Cancer].[铂类双联再激发化疗治疗复发性晚期非小细胞肺癌患者的疗效和安全性评估]
Gan To Kagaku Ryoho. 2016 Jun;43(6):723-6.
7
Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.纳武利尤单抗治疗晚期非小细胞肺癌患者进展后疗效和安全性的研究
Clin Lung Cancer. 2019 May;20(3):178-185.e2. doi: 10.1016/j.cllc.2019.02.001. Epub 2019 Feb 27.
8
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.T790M突变在EGFR突变的晚期肺腺癌患者EGFR-TKI再挑战治疗中的作用。
Oncotarget. 2017 Jan 17;8(3):4994-5002. doi: 10.18632/oncotarget.14007.
9
Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.真实世界研究：阿法替尼一线或二线治疗表皮生长因子受体突变型非小细胞肺癌患者。
Med Oncol. 2019 May 14;36(6):57. doi: 10.1007/s12032-019-1278-9.
10
Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database.非小细胞肺癌患者在靶向或免疫治疗进展后接受转移灶定向立体定向放疗：来自 'TOaSTT' 数据库的疗效和安全性报告。
Radiat Oncol. 2021 Jan 6;16(1):4. doi: 10.1186/s13014-020-01730-0.

引用本文的文献

1
Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive mutations.对于携带敏感突变的晚期非小细胞肺癌患者，在疾病进展后继续使用吉非替尼进行再治疗。
J Int Med Res. 2020 Oct;48(10):300060520955030. doi: 10.1177/0300060520955030.
2
Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge.酪氨酸激酶抑制剂进展后再治疗：选择与挑战。
J Thorac Dis. 2014 Jun;6(6):595-7. doi: 10.3978/j.issn.2072-1439.2014.04.36.

本文引用的文献

1
Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.表皮生长因子受体酪氨酸激酶抑制剂超越进展期疾病：一项针对日本激活型 EGFR 突变患者的回顾性分析。
J Thorac Oncol. 2012 Nov;7(11):1722-7. doi: 10.1097/JTO.0b013e31826913f7.
2
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.ALK 阳性非小细胞肺癌患者中克唑替尼的活性和安全性：来自一项 I 期研究的更新结果。
Lancet Oncol. 2012 Oct;13(10):1011-9. doi: 10.1016/S1470-2045(12)70344-3. Epub 2012 Sep 4.
3
Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.克服晚期 NSCLC 治疗中 EGFR 耐药的策略。
Curr Treat Options Oncol. 2012 Dec;13(4):516-26. doi: 10.1007/s11864-012-0204-6.
4
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.厄洛替尼单药或联合卡铂和紫杉醇治疗从不吸烟或轻度吸烟的晚期肺腺癌患者的随机 II 期试验：CALGB 30406 试验。
J Clin Oncol. 2012 Jun 10;30(17):2063-9. doi: 10.1200/JCO.2011.40.1315. Epub 2012 Apr 30.
5
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.ALK 基因重排非小细胞肺癌患者对克唑替尼耐药的机制。
Clin Cancer Res. 2012 Mar 1;18(5):1472-82. doi: 10.1158/1078-0432.CCR-11-2906. Epub 2012 Jan 10.
6
ROS1 rearrangements define a unique molecular class of lung cancers.ROS1 重排定义了一类独特的肺癌分子亚型。
J Clin Oncol. 2012 Mar 10;30(8):863-70. doi: 10.1200/JCO.2011.35.6345. Epub 2012 Jan 3.
7
Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?表皮生长因子受体-酪氨酸激酶抑制剂在疾病进展后是否应继续使用？
Case Rep Oncol. 2011 Sep;4(3):470-4. doi: 10.1159/000332758. Epub 2011 Sep 20.
8
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.克唑替尼治疗携带 ALK 基因重排的晚期非小细胞肺癌患者的总生存影响：一项回顾性分析。
Lancet Oncol. 2011 Oct;12(11):1004-12. doi: 10.1016/S1470-2045(11)70232-7. Epub 2011 Sep 18.
9
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.表皮生长因子受体突变型肺癌细胞系获得性耐药表皮生长因子受体酪氨酸激酶抑制剂后上皮间质转化。
J Thorac Oncol. 2011 Jul;6(7):1152-61. doi: 10.1097/JTO.0b013e318216ee52.
10
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.获得性 EGFR 抑制剂耐药的肺癌的基因和组织学演变。
Sci Transl Med. 2011 Mar 23;3(75):75ra26. doi: 10.1126/scitranslmed.3002003.